Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 22 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
CITY-PHARMA from Antwerpen, company number BE0891813644, closed financial year 2025 with a result of € -112,104 after tax. For that financial year CITY-PHARMA recorded a gross margin of € 137,866 and equity of € -237,822. Compared with financial year 2024, the result moved from € -44,629 to € -112,104. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ -237,822
▼ € 112,104 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -112,104
▼ 151 % more loss than in 2024
Profit after tax over the fiscal year.
€ 38,244
▲ 17% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -256,422.
People and assets in 2025
3.4
▲ 0.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 185,531
▲ 4% vs 2024
€ 54,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 21,859
▼ 25% vs 2024
Of which on lease € 21,859.
Debts at end 2025
€ 175,575
▼ 11% vs 2024
€ 38,146 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 142,978
▲ 21% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 24,517
▲ 36% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 202,471 | € 171,108 | € 182,390 | € 137,866 | ▼ 24% |
| Profit after taxes | € 39,472 | € -109,918 | € -44,629 | € -112,104 | ▼ € 67,475 |
| Equity | € 28,828 | € -81,089 | € -125,718 | € -237,822 | ▼ € 112,104 |
| Total debts | € 348,429 | € 503,822 | € 673,536 | € 716,774 | ▲ 6% |
| Cash | € 24,819 | € 41,863 | € 32,616 | € 38,244 | ▲ 17% |
| Retained profit | € 10,228 | € -99,689 | € -144,318 | € -256,422 | ▼ € 112,104 |
| Bank debt | € 123,670 | € 93,919 | € 196,464 | € 175,575 | ▼ 11% |
| Balance sheet total | € 377,257 | € 422,732 | € 547,817 | € 478,952 | ▼ 13% |
| Employees (FTE) | 1.9 | 3.1 | 3 | 3.4 | ▲ 0.4 |
Key figures of CITY-PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CITY-PHARMA?
What happened at CITY-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 112,104. Source: NBB ↗
- Ortegawynter BV became a director. NBB
- Start of the company according to the CBE. KBO
- New establishment in Antwerpen. KBO
- T&M Pharma BV became a director. NBB
In short
From € 39,472 profit in 2022 to € 112,104 loss in 2025.
Paid € 11,560 in corporate taxes since 2022.
Best year ever: 2022, with € 39,472 profit.
On average € 40,500 of value added per employee in 2025.
A new publication or filing at CITY-PHARMA? We notify you, reason included.
Follow CITY-PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind CITY-PHARMA are Ortegawynter BV and T&M Pharma BV. The same people are also behind Kapelle Apotheek, CAM Immo, Apotheek Stabroek, Immobox and Apoplus. T&M Pharma BV is also behind Apotheek Willebroek.
Directors
According to the 2025 annual accounts
Director · represented by Carlos Ortega Saez
Also active at: Kapelle Apotheek, CAM Immo, Apotheek Stabroek, Immobox, Apoplus, STAB Immo
since 2013
Director · represented by Mieke Raemdonck
Also active at: Apotheek Willebroek, Kapelle Apotheek, CAM Immo, Apotheek Stabroek, Immobox, Apoplus, STAB Immo
since 2007
Establishments
Establishment units
Physical locations of this company
Kammenstraat 61
2000 Antwerpen
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0891.813.644
- VAT number
- BE 0891.813.644
- Registered office
- Kammenstraat 61, 2000 Antwerpen
- Names & denominations
- CITY-PHARMA · PHARMAZONE
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 September 2007
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers